CN113316453B - 用于提高转录因子eb多肽水平的方法和材料 - Google Patents

用于提高转录因子eb多肽水平的方法和材料

Info

Publication number
CN113316453B
CN113316453B CN202080007921.4A CN202080007921A CN113316453B CN 113316453 B CN113316453 B CN 113316453B CN 202080007921 A CN202080007921 A CN 202080007921A CN 113316453 B CN113316453 B CN 113316453B
Authority
CN
China
Prior art keywords
alkyl
independently selected
compound
formula
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080007921.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113316453A (zh
Inventor
B·陈
T·芬克尔
Y·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of CN113316453A publication Critical patent/CN113316453A/zh
Application granted granted Critical
Publication of CN113316453B publication Critical patent/CN113316453B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
CN202080007921.4A 2019-01-03 2020-01-03 用于提高转录因子eb多肽水平的方法和材料 Active CN113316453B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962788049P 2019-01-03 2019-01-03
US62/788,049 2019-01-03
US201962879374P 2019-07-26 2019-07-26
US62/879,374 2019-07-26
PCT/US2020/012268 WO2020142748A1 (en) 2019-01-03 2020-01-03 Methods and materials for increasing transcription factor eb polypeptide levels

Publications (2)

Publication Number Publication Date
CN113316453A CN113316453A (zh) 2021-08-27
CN113316453B true CN113316453B (zh) 2025-12-23

Family

ID=71406977

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080007921.4A Active CN113316453B (zh) 2019-01-03 2020-01-03 用于提高转录因子eb多肽水平的方法和材料

Country Status (12)

Country Link
US (2) US12286442B2 (https=)
EP (1) EP3906033A4 (https=)
JP (1) JP7566753B2 (https=)
KR (1) KR102904932B1 (https=)
CN (1) CN113316453B (https=)
AU (1) AU2020204717B2 (https=)
BR (1) BR112021012950A2 (https=)
CA (1) CA3123902A1 (https=)
IL (1) IL284403A (https=)
MX (1) MX2021008152A (https=)
SG (1) SG11202105685TA (https=)
WO (1) WO2020142748A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533016A (ja) 2020-07-11 2023-08-01 ファイザー・インク 抗ウイルス性ヘテロアリールケトン誘導体
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CZ309449B6 (cs) * 2020-12-24 2023-01-25 Ústav experimentální botaniky AV ČR, v. v. i. Chinazolinové deriváty jako selektivní inhibitory cyklooxygenázy-1
CN113248518B (zh) * 2021-06-21 2022-03-25 山东大学 嘧啶哌嗪类衍生物及其制备方法与应用
CN121941701A (zh) * 2023-07-28 2026-04-28 特兰埃克斯公司 用于治疗溶酶体病症的突变tfeb
CN119818678A (zh) * 2024-12-24 2025-04-15 广州医科大学附属妇女儿童医疗中心 Tfeb在制备变应性鼻炎的药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057695A1 (en) * 2001-12-21 2003-07-17 Boehringer Ingelheim Pharmaceuticals, Inc. 1,6 naphthyridines useful as inhibitors of syk kinase
CN1469874A (zh) * 2000-09-15 2004-01-21 ��̩��˹ҩ��ɷ����޹�˾ 可用作蛋白激酶抑制剂的吡唑化合物
WO2010015520A1 (de) * 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituierte naphthyridine und ihre verwendung als arzneimittel
WO2010015518A2 (de) * 2008-08-05 2010-02-11 Boehringer Ingelheim Interntional Gmbh 4-dimethylamino-phenyl-substituierte naphthyridine und ihre verwendung als arzneimittel
CN102947306A (zh) * 2010-04-29 2013-02-27 葛兰素集团有限公司 作为syk抑制剂的7-(1h-吡唑-4-基)-1,6-萘啶化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
AU2003286711A1 (en) * 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
CL2004000409A1 (es) 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
US7198926B2 (en) * 2003-05-08 2007-04-03 E. I. Du Pont De Nemours And Company Preparation of (E)- and (Z)-2-methyl-2-butenoic acids
EP1622615A4 (en) 2003-05-13 2009-02-18 Smithkline Beecham Corp INHIBITORS OF THE INTEGRASE OF NAPHTHYRIDINE
WO2008157500A1 (en) * 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
CA2705303A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
CN104812387A (zh) 2012-11-20 2015-07-29 霍夫曼-拉罗奇有限公司 取代的1,6-萘啶
CN107205976A (zh) * 2014-11-19 2017-09-26 拉什大学医学中心 用于治疗溶酶体病症的组合物和方法
WO2018089433A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
WO2018089499A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
WO2018089493A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PYRROLE mTORC INHIBITORS AND USES THEREOF
WO2018191146A1 (en) * 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1469874A (zh) * 2000-09-15 2004-01-21 ��̩��˹ҩ��ɷ����޹�˾ 可用作蛋白激酶抑制剂的吡唑化合物
WO2003057695A1 (en) * 2001-12-21 2003-07-17 Boehringer Ingelheim Pharmaceuticals, Inc. 1,6 naphthyridines useful as inhibitors of syk kinase
WO2010015520A1 (de) * 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituierte naphthyridine und ihre verwendung als arzneimittel
WO2010015518A2 (de) * 2008-08-05 2010-02-11 Boehringer Ingelheim Interntional Gmbh 4-dimethylamino-phenyl-substituierte naphthyridine und ihre verwendung als arzneimittel
CN102947306A (zh) * 2010-04-29 2013-02-27 葛兰素集团有限公司 作为syk抑制剂的7-(1h-吡唑-4-基)-1,6-萘啶化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
1, 3, 4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2 SAR of the C5 position;Johns B A等;Bioorganic & Medicinal Chemistry Letters;第19卷(第6期);表1-3 *
The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1 Establishing the pharmacophore;Johns B A等;Bioorganic & Medicinal Chemistry Letters;第19卷(第6期);表2 *

Also Published As

Publication number Publication date
KR20210111787A (ko) 2021-09-13
BR112021012950A2 (pt) 2021-09-14
US12286442B2 (en) 2025-04-29
AU2020204717A1 (en) 2021-06-10
CA3123902A1 (en) 2020-07-09
JP2022516631A (ja) 2022-03-01
SG11202105685TA (en) 2021-06-29
CN113316453A (zh) 2021-08-27
US20250382309A1 (en) 2025-12-18
EP3906033A1 (en) 2021-11-10
US20220112218A1 (en) 2022-04-14
AU2020204717B2 (en) 2025-01-16
IL284403A (en) 2021-08-31
MX2021008152A (es) 2021-10-13
EP3906033A4 (en) 2022-11-09
JP7566753B2 (ja) 2024-10-15
KR102904932B1 (ko) 2025-12-26
WO2020142748A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
CN113316453B (zh) 用于提高转录因子eb多肽水平的方法和材料
JP6782255B2 (ja) ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法
EP3786167B1 (en) Diaryl macrocyclic compound and pharmaceutical composition, and use thereof
JP6851825B2 (ja) 非アポトーシス性の制御された細胞死の阻害剤としてのスピロキノキサリン誘導体
JPWO2003091256A1 (ja) ピラゾロ［１，５−ａ］ピリミジン誘導体およびそれを含有するＮＡＤ（Ｐ）Ｈオキシダーゼ阻害剤
WO2013036912A2 (en) Amido compounds as rorϒtmodulators and uses thereof
CN110914253A (zh) 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
CN110023311A (zh) 2-取代的氨基-萘并[1,2-d]咪唑-5-酮类化合物或其药学上可接受的盐
JP2021523934A (ja) ミトコンドリア脱共役剤として有用なアミノピラジンおよび関連化合物
CN109748914B (zh) 吡啶并嘧啶类化合物及其应用
TW201331202A (zh) ［１，２，４］三唑并吡啶及其作為磷酸二酯酶抑制劑之用途
KR20220118483A (ko) Oga 억제제 화합물
CN105130884B (zh) 5‑甲基‑2(1h)吡啶酮衍生物及其制备方法和用途
RU2838857C2 (ru) Способы и материалы для повышения уровней полипептида фактора транскрипции eb
WO2021094312A1 (en) Pyrrolidine and bicycloheteroaryl containing oga inhibitor compounds
US20250154150A1 (en) Substituted fused ring compound, pharmaceutical composition thereof, preparation method therefor and uses thereof
CN102408395B (zh) 新的哌嗪和高哌嗪类衍生物及其制备方法和应用
US20260076959A1 (en) Combination product, salt, and use thereof in treating neurodegenerative diseases or disorders
CN113072562B (zh) 一种GSK-3β抑制剂及其制备方法与应用
CN113801135B (zh) 噻吩并吡唑类化合物，包含其的药物组合物及其用途
DE60216807T2 (de) Triazepin-derivate als neurotrope mittel
CN121342760A (zh) 一种二酮哌嗪类铁死亡抑制剂及其制备方法和应用
WO2023193809A1 (zh) Sarm1抑制剂化合物、包含其的药物组合物及其制备方法和用途
JP2025517688A (ja) Ｌｒｒｋ２阻害剤
JP2025521097A (ja) Ｌｒｒｋ２阻害剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant